Actue Kindey Disease (AKD) Models and Efficacy Services

Anti-Tumor Drug Efficacy Evaluation
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Autoimmune Disease Efficacy Evaluation
Autoimmune Nephropathy Models and Efficacy ServicesAsthma Models and Efficacy ServicesSystemic Lupus Erythematosus (SLE) Models and Efficacy ServicesSjögren's Syndrome Models and Efficacy ServicesNeuroimmune Diseases Models and Efficacy ServicesAutoimmune Dermatoses Models and Efficacy ServicesInflammatory Bowel Disease (IBD) Models and Efficacy ServicesRheumatoid Arthritis (RA) Models and Efficacy ServicesImmune Reconstitution Autoimmune Disease Models and Efficacy Services
Metabolic Disease Efficacy Evaluation
Obesity Models and Efficacy ServicesType II Diabetes Models and Efficacy ServiceType I Diabetes Models and Efficacy ServicesAndrogenetic Alopecia (AGA) Models and Efficacy ServicesMASH Models and Efficacy ServicesChronic Liver Fibrosis Models and Efficacy ServicesAcute Liver Injury Models and Efficacy ServicesCholestasis Models and Efficacy ServicesAlcohol-related Liver Disease (ALD) Models and Efficacy ServicesChronic Kindey Disease (CKD) Models and Efficacy ServicesActue Kindey Disease (AKD) Models and Efficacy ServicesDiabetes Nephropathy (Diabetic Kidney Disease) Models and Efficacy ServicesSarcopenia Models and Efficacy ServicesGout/Hyperuricemia Models and Efficacy ServicesFemale Reproduction Models and Efficacy Services
Neurological Disease Efficacy Evaluation
Behavioral AnalysisIn Vivo Drug Efficacy EvaluationDelivering Therapeutics Across the Blood-Brain Barrier (BBB)Parkinson’s Disease Rat Model
Cardiovascular Diseases Efficacy Evaluation
Heart Failure Models and Efficacy ServicesHypertension Models and Efficacy ServicesAtherosclerosis Models and Efficacy ServicesAdvanced Cardiovascular and Metabolic Complication Models and Efficacy ServicesHyperlipidemia Models and Efficacy ServicesHypertropic Cardiomyopathy Models and Efficacy ServicesStroke Models and Efficacy ServicesThrombosis Models and Efficacy Services
Infectious Disease Efficacy Evaluation
About Our Biosafety LaboratoryIn vitro Drug Efficacy EvaluationIn vivo Drug Dfficacy Evaluation
Respiratory Disease Efficacy Evaluation
Acute Lung Injury (ALI) ModelsIdiopathic Pulmonary Fibrosis (IPF) ModelsChronic Obstructive Pulmonary Disease (COPD) ModelsBronchiectasis ModelsPulmonary Function Test
Disease Rat Models
60% HFD Induced DIO Rat ModelsHFHSD+STZ Induced Type II Diabetes Model in SD Rat45％HFHS+STZ Induced Type I Diabetes Models in SD RatCDAHFD-induced Rat MASH ModelCCL4-induced Chronic Liver Fibrosis Models in SD Rat5/6 Nephrectomy-induced Rat CKD ModelAdenine-induced Rat CKD ModelOVX-induced Rat Osteoporosis Model2K1C-induced Hypertension Model in SD RatMCAO-induced CIS Model in SD Rat
Bioanalytical Services
Phenotyping Services
Oncology PlatformMetabolism PlatformEfficacy and Pathology Platform
Non-GLP Toxicity Assessment Services
Cell Therapy & Gene Therapy Efficacy Evaluation

Acute kidney disease, or acute kidney injury (AKI), is characterized by a rapid and often severe decline in kidney function, typically occurring within hours to days. Triggered by diverse factors—severe dehydration, blood loss, sepsis, certain medications like antibiotics and chemotherapy drugs, and impaired renal blood flow—AKI disrupts the kidneys' ability to filter waste, regulate fluid - electrolyte balance, and maintain blood pressure. Symptoms manifest as decreased urine output, swelling, fatigue, nausea, and confusion. Without timely treatment, it can progress to life-threatening complications, including electrolyte disorders, fluid overload, and multi-organ failure. Yet, with prompt diagnosis and proper medical care, many patients can regain normal or near-normal kidney function.


Cisplatin is a widely used chemotherapeutic agent, but due to its significant nephrotoxicity, it is commonly employed to establish AKI animal models. Cisplatin primarily induces renal injury by accumulating in renal tubular cells, causing DNA damage, mitochondrial dysfunction, and cell apoptosis or necrosis. It also reduces renal blood flow, leading to local ischemia and decreased glomerular filtration rate (GFR). This model effectively mimics the pathological features of renal injury observed in patients receiving chemotherapy, including tubular necrosis, inflammatory responses, and oxidative stress, making it a classic experimental tool for studying AKI pathogenesis and evaluating potential nephroprotective therapies.


Study Design


图片1.png


Example Data

Single cisplatin treatment causes kidney injury in a time-dependent manner 


2.jpeg


Single cisplatin treatment results in mortality in a dose dependent manner 


3.png


Single cisplatin treatment results in severe tubular damage (tubular protein): Kidney histology (H&E Staining) 


4.png

5.png


Single cisplatin exposure causes mild inflammation in lung: Lung histology (H&E Staining)


6.png

7.png

TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.